Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. [electronic resource]
Producer: 20171013Description: 4975-4986 p. digitalISSN:- 1476-5594
- Animals
- Benzamides -- pharmacology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Colorectal Neoplasms -- drug therapy
- Cyclin-Dependent Kinase 4 -- antagonists & inhibitors
- Cyclin-Dependent Kinase 6 -- antagonists & inhibitors
- Diphenylamine -- analogs & derivatives
- Female
- Gene Expression Profiling
- HCT116 Cells
- HT29 Cells
- Humans
- MAP Kinase Kinase Kinases -- antagonists & inhibitors
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Molecular Targeted Therapy
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins p21(ras) -- genetics
- Pyridines -- pharmacology
- Random Allocation
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.